PDZD2

Across TCGA pan-cancer cohorts, PDZD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDZD2 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDZD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDZD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where PDZD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.869	.005	18	view →
LUAD	DFS	Tertile	All	0.770	0.996	.007	13	view →
HNSC	DFS	Median	III,IV	1.000	0.901	.025	1	view →
LSCC	DFS	Median	All	0.472	0.851	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDZD2–CCRCC (OS)

Open the CCRCC breakdown →